Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain
- PMID: 3839265
Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain
Abstract
Membranes prepared from rat cerebral cortex were solubilized in buffer containing 1% digitonin. Material present in the supernatant after centrifugation at 147,000 X g was shown to contain binding sites for both [3H]quinuclidinyl benzilate [( 3H]QNB) and [3H]pirenzepine [( 3H]PZ). Recovery of binding sites was approximately 25% of the initial membrane-bound [3H]QNB binding sites. The Kd values for [3H]QNB and [3H]PZ binding to solubilized receptors were 0.3 nM and 0.1 microM, respectively. As has been observed previously in membrane preparations, [3H]PZ appeared to label fewer solubilized binding sites than did [3H]QNB. Maximum binding values for [3H]PZ and [3H]QNB binding to solubilized receptors were approximately 400 and 950 fmol/mg of protein, respectively. Competition curves for PZ inhibiting the binding of [3H]QNB, however, had Hill slopes of 1, with a Ki value of 0.24 microM. The k1 and k-1 for [3H]PZ binding were 3.5 X 10(6) M-1 min-1 and 0.13 min-1, respectively. The muscarinic receptor antagonists atropine, scopolamine and PZ inhibited the binding of [3H]QNB and [3H]PZ to solubilized receptors with Hill slopes of 1, as did the muscarinic receptor agonist oxotremorine. The muscarinic receptor agonist carbachol competed for [3H]QNB and [3H]PZ binding with a Hill slope of less than 1 in cerebral cortex, but not in cerebellum. GTP did not alter the interactions of carbachol or oxotremorine with the solubilized receptor. Together, these data suggest that muscarinic receptor sites solubilized from rat brain retain their abilities to interact selectively with muscarinic receptor agonists and antagonists.
Similar articles
-
Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.J Pharmacol Exp Ther. 1984 Mar;228(3):648-55. J Pharmacol Exp Ther. 1984. PMID: 6546770
-
[3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.J Pharmacol Exp Ther. 1986 May;237(2):419-27. J Pharmacol Exp Ther. 1986. PMID: 3754581
-
[3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.J Pharmacol Exp Ther. 1986 May;237(2):411-8. J Pharmacol Exp Ther. 1986. PMID: 3754580
-
On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.Acta Pharmacol Toxicol (Copenh). 1986;59 Suppl 1:1-45. Acta Pharmacol Toxicol (Copenh). 1986. PMID: 3524114 Review.
-
Biochemical indentification of the mammalian muscarinic cholinergic receptor.Fed Proc. 1975 Sep;34(10):1915-21. Fed Proc. 1975. PMID: 808430 Review.
Cited by
-
Cholinergic mediation of the discriminative stimulus properties of clozapine.Psychopharmacology (Berl). 1988;94(1):115-8. doi: 10.1007/BF00735891. Psychopharmacology (Berl). 1988. PMID: 3126519
-
Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex.J Neural Transm. 1988;72(1):11-8. doi: 10.1007/BF01244628. J Neural Transm. 1988. PMID: 3379385
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials
Miscellaneous